Previewing the 2025 Revolutionizing Atopic Dermatitis Conference

The 2025 Revolutionizing Atopic Dermatitis (RAD) conference begins today in Nashville, Tennessee, and concludes on Saturday, June 7. The 2-day conference packs back-to-back sessions on the latest advancements in atopic dermatitis (AD).¹

RAD founder, Jonathan Silverberg, MD, PhD, MPH, joins co-chair Raj Chovatiya, MD, PhD, MSCI, in leading this year’s events. Silverberg, professor of dermatology and director of clinical research and contact dermatitis at the George Washington University School of Medicine and Health Sciences in Washington, DC, will lead attendees through updates on the latest approvals in AD and what clinicians need to know alongside Leon Kircik, MD.

Chovatiya, clinical associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and a Dermatology Times Editorial Advisory Board member, will discuss dose flexibility in adult patients with AD and how to differentiate between IL-31 and IL-13.

Day 1 sessions at RAD include:

• The Psychosocial Burden of AD with Mona Shahriari, MD
• JAK Inhibitors in AD Management with Andrew Alexis, MD, MPH, and Leon Kircik, MD
• Complex Cases: AD and Hair Loss with Tiffany Mayo, MD
• Managing Itch with Andrew Alexis, MD, MPH, and Gil Yosipovitch, MD
• Understanding Topical Steroid Withdrawal in Patients with AD with Diego Ruiz Dasilva, MD; Brad Glick, DO, MPH; and Peter Lio, MD

Day 2 sessions at RAD include:

• Pediatric AD with Anne-Marie Singh, MD, and Lisa Swanson, MD
• Pediatric AD: Patient, Provider, Caregiver Connection with Peter Lio, MD
• Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of AD with Johann Gudjonsson, MD, PhD, and Christopher Bunick, MD, PhD
• Chronic Hand Eczema with JiaDe “Jeff” Yu, MD, MS, and G. Scott Drew, DO
• Dose Flexibility in Adult AD with Raj Chovatiya, MD, PhD, MSCI; Tejesh Patel, MD; and G. Scott Drew, DO
• Medical Crossfire: IL-31 and IL-13 with Raj Chovatiya, MD, PhD, MSCI; Christopher Bunick, MD, PhD; and Matthew Zirwas, MD

Additionally, the second day of RAD concludes with fan-favorite oral presentations on late-breaking research in AD.

Click here to view the full agenda

After the conference, attendees should be able to²:

• Evaluate the efficacy, safety, and mechanisms of action of available treatments for AD, including biologics, JAK inhibitors, and topical therapies, while discussing emerging options in the pipeline.
• Apply patient-centric approaches to AD management, incorporating disease severity, comorbidities, and patient preferences to optimize outcomes.
• Review and implement guideline-directed care for AD, focusing on age-specific recommendations and treatment algorithms.
• Utilize effective communication techniques to improve patient adherence, manage expectations, and address concerns related to treatment options.

Dermatology Times is onsite at the DoubleTree by Hilton Nashville to gather the latest and greatest expert insights, therapeutic pearls, and practice management techniques in AD. Interested in connecting with us? Message Dermatology Times on LinkedIn for the opportunity to collaborate.

Keep up to date with the latest in coverage from RAD 2025 by subscribing to Dermatology Times to receive daily email updates, and follow along on social media on LinkedIn, Facebook, and X.

References

1. Revolutionizing Atopic Dermatitis (RAD) Conference 2025 agenda. Physician's Education Resource. Accessed June 5, 2025. https://registration.gotoper.com/rad-2025/agenda
2. Revolutionizing Atopic Dermatitis (RAD) Conference 2025 learning objectives. Physician's Education Resource. Accessed June 5, 2025. https://www.gotoper.com/courses/rad